Product image of Lenalidomide Reddy Pharma (Lenalidomide) supplied by GNH India

Lenalidomide Reddy Pharma

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Reddy Pharma (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Reddy Pharma, is an immunomodulatory imide drug (IMiD) presented as an oral dosage form for oral use. Originating from the European Union market, it is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomide Reddy Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Reddy Pharma Sas

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

  • Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
  • Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality.
  • Mantle Cell Lymphoma: contributes to disease control in patients with relapsed or refractory mantle‑cell lymphoma.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This results in cytokine modulation, anti‑angiogenic activity, and direct anti‑myeloma effects through apoptosis and immune‑mediated tumor cell clearance.

Side Effects

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may require fluid replacement.
  • Nausea: feeling of sickness often occurring after dosing.
  • Rash: mild skin eruptions or itching.
  • Constipation: reduced bowel movements causing discomfort.
  • Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: marked reduction in neutrophil count increasing infection risk.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Secondary primary malignancies: emergence of new cancers.
  • Stevens‑Johnson syndrome: severe skin reaction with blistering.
  • Pregnancy loss: fetal toxicity leading to miscarriage.

Precautions & Warnings

When prescribing Lenalidomide, clinicians should observe several safety precautions.

  • Pregnancy contraindication: avoid use in pregnancy due to teratogenic risk (Category X).
  • Thromboembolism risk: assess patient history and consider prophylactic anticoagulation.
  • Renal impairment: adjust therapy in patients with reduced kidney function.
  • Hepatic dysfunction: monitor liver function tests regularly.
  • Infection monitoring: watch for signs of infection due to neutropenia.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Lenalidomide has several drug interaction considerations that can affect efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lenalidomide exposure.
  • Anticoagulants (warfarin, DOACs): increase risk of bleeding when combined with lenalidomide‑associated thrombocytopenia.
  • Immunosuppressants (cyclosporine, tacrolimus): may enhance immunosuppressive effects.

Moderate Interactions (Monitor Closely)

  • P‑glycoprotein inhibitors: can increase plasma concentrations.
  • NSAIDs: may exacerbate gastrointestinal irritation.
  • Vaccines (live attenuated): reduced efficacy due to immunomodulation.

Frequently Asked Questions

Lenalidomide Reddy Pharma is indicated for adult patients with multiple myeloma, myelodysplastic syndromes that have a del(5q) chromosomal abnormality, and mantle cell lymphoma, particularly in relapsed or refractory disease settings.

The drug binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This triggers immunomodulation, anti‑angiogenic effects, and direct anti‑tumor activity against malignant plasma cells.

The specific dose and schedule are determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Prescribers follow approved labeling and clinical guidelines to individualise therapy.

Lenalidomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women, and breastfeeding is not recommended as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is a second‑generation IMiD offering greater potency and a more favourable safety profile than thalidomide, while providing similar immunomodulatory effects. Compared with pomalidomide, it is often used earlier in therapy lines and has a longer clinical experience base.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain stability.

Lenalidomide is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations.

Serious risks include thromboembolic events such as deep‑vein thrombosis, severe neutropenia leading to infection, hepatotoxicity, secondary primary malignancies, and fetal toxicity resulting in pregnancy loss. Patients should be monitored closely for these events.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to the drug, patients with uncontrolled infections, or those with severe renal or hepatic impairment unless dose adjustments are made under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT